Back to search results

Linvoseltamab for Relapsed/Refractory Multiple Myeloma

This study is for adults with multiple myeloma (a type of blood cancer) that has returned or not responded to previous treatments (relapsed/refractory multiple myeloma, RRMM). You must have received 1 to 3 prior treatments, including lenalidomide and either a proteasome inhibitor (PI) or an anti-CD38 monoclonal antibody. The study is comparing linvoseltamab alone or with carfilzomib, to standard treatments like daratumumab, dexamethasone, and pomalidomide. Researchers want to see if linvoseltamab is safe and effective in improving outcomes. The study plans to enroll 915 participants. The current status of the study is unclear.

Study design
This is an interventional study planning to enroll 915 participants. It compares different drug combinations for relapsed/refractory multiple myeloma.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be monitored for side effects for up to 5 years after treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07222761

A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

Recruiting
PHASE3Ages 18+InterventionalTreatment
Regeneron Pharmaceuticals
~915 participants
Updated 2026-07-01 on ClinicalTrials.gov
What's tested:LinvoseltamabCarfilzomibDaratumumabDexamethasonePomalidomideBortezomib

At a glance

Recruiting sites
20 of 20 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Occurrence of Treatment Emergent Adverse Events (TEAEs)
Measured over Up to 5 years
+7 more outcomes measured

Conditions

Relapsed and/or Refractory Multiple Myeloma (RRMM)

Explore related trials

Multiple Myeloma

Where it's being run

20 sites across 14 states
South Korea6
Queensland2
Georgia1
New York1
Ohio1
Texas1
Victoria1
Jeollanam-do1

Study leadership

  • Clinical Trial Management · STUDY_DIRECTOR · Regeneron Pharmaceuticals

Who to contact

Clinical Trials Administrator
[email protected]
844-734-6643
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

What this trial measures

  • Occurrence of Treatment Emergent Adverse Events (TEAEs)Up to 5 years

    Part 1

  • Severity of TEAEsUp to 5 years

    Part 1

  • Occurrence of Adverse Events of Special Interest (AESI)Up to 5 years

    Part 1

  • Severity of AESIsUp to 5 years

    Part 1

  • Occurrence of Serious Adverse Events (SAEs)Up to 5 years

    Part 1

  • Severity of SAEsUp to 5 years

    Part 1

  • Minimal Residual Disease (MRD)-negative Complete Response (CR)At 12 months

    Part 2

  • Progression-Free Survival (PFS) per IMWG response criteria as determined by BIRCUp to 5 years

    Part 2